Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q2 2018 · 10-Q
Revenue$61.51M$61.51M+60.3% vs Q2 2017 Net Income-$15.51M-$15.51MN/M vs Q2 2017 EPS Diluted-$0.17-$0.17N/M vs Q2 2017 Gross Profit$41,681,000+65.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow-$7,493,000N/M Free Cash Flowderived-$8,347,000N/M Margins · derivedGross margin67.8%+2.0 pt vs Q2 2017
Operating margin-11.5%+29.0 pt vs Q2 2017
Net margin-25.2%+30.0 pt vs Q2 2017
ended Jun 30, 2018 · filed Jul 26, 2018 · 26 d after period end